Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

A next-generation PCR tool for rapid and early diagnosis of sepsis aetiology

Objectif

Sepsis is a life-threatening condition caused by a dysregulated immune response to infection, responsible for over 11M deaths annually. Rapid identification of the causative pathogen is essential, as each hour of delay in targeted treatment increases mortality by ~8%. Current diagnostics, such as blood culture, are slow (up to five days) and frequently yield false negatives, while existing PCR-based tools remain limited by narrow pathogen panels, low sensitivity in whole blood, and dependence on complex, costly instrumentation.

The SURPASS project, led by DIANA Biotechnologies, will advance SepsiSense, a next-generation molecular diagnostic tool enabling rapid, ultra-sensitive detection of sepsis-causing pathogens directly from whole blood. SepsiSense integrates proprietary PCR enzymes, inhibitor-resistant chemistry, and a novel deep multiplex design capable of detecting ~30 bacterial and fungal pathogens, and antibiotic resistance genes in a single reaction. Its unique RNA–DNA co-detection approach provides superior sensitivity and enables assessment of pathogen viability and resistance activity, delivering clinically actionable results within 2 hours.

Through SURPASS, DIANA will mature SepsiSense from early TRL 4 to TRL 6, expanding the pathogen panel, validating the assay across commercial PCR platforms, and aligning performance with IVDR standards. In parallel, the project will strengthen DIANA’s business and investor readiness through development of a market-validated business plan, IP and regulatory strategy, and partnerships with hospitals, KOLs, and diagnostic companies.

Offering high performance, affordability (~€25/test), and compatibility with existing PCR systems, SepsiSense will enable faster, more accurate diagnostics, support antibiotic stewardship, and reinforce Europe’s leadership and autonomy in advanced molecular healthcare technologies.

Champ scientifique (EuroSciVoc)

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-CSA - HORIZON Coordination and Support Actions

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-WIDERA-2025-02

Voir tous les projets financés au titre de cet appel

Coordinateur

DIANA Biotechnologies, a.s.
Contribution nette de l'UE
€ 498 969,10
Adresse
Prumyslova 596
252 50 Vestec
Tchéquie
PME
Oui
Région
Česko Střední Čechy Středočeský kraj
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
Aucune donnée